Partner
Brief description of institution/company
Abcam is a global biotechnology company specialising in reagents and kits for research. We have over 700 employees globally working research, production and administration. Our focus is on enabling scientists to discover more, with our high-quality protein research tools, expert technical support, fast global delivery, and up-to-date and honest data.
Scientists
Dr. Gary P. Dillon
Department
Technology and R&D
Role in Consortium
Training and Secondments
Brief CV
| since 2010 | Joined Abcam Cambridge as a Senior scientist, Head of R&D from 2013. |
| 2009 - 2010 | Post Doctoral researcher at the Wellcome Trust Sanger insitute. |
| 2006 - 2009 | Post Doctoral researcher at University of York, UK |
| 2002 - 2006 | PhD thesis Parasitology, University of York, UK |
| 1998 - 2002 | Undergraduate reading Biochemistry, University of York, UK |
Keywords Research Activities
- Antibody generation and engineering
- Display techniques for in vitro selection
- Alternative scaffolds
- Next generation sequencing/bioinformatics
- Imaging techniques
Key publications or research/innovation products
- Otto T.D.; Dillon G.P.; Degrave W.S.; Berriman M. (2010) RATT: Rapid Annotation Transfer Tool. Nucleic Acids Res. 1;39(9):e57
- Berriman, M.; Haas, B.; LoVerde, P.T.; Wilson, R.A.; Dillon, G.P.; Cerqueira, G.C. et al. (2009) The Genome of the blood fluke Schistosoma mansoni. Nature. 460(7253):352-8.
- Wilson, R.A.; Langermans, J.A.M.; Van Dam, G.J.; Vervenne, R.A.; Hall, S.L.; Borges, W.C.; Dillon, G.P.; Thomas, A.W.; Coulson, P.S. (2008) Elimination of Schistosoma mansoni adult worms by rhesus macaques: basis for a therapeutic vaccine? PLoS Negl Trop Dis. 2(9):e290.
- Dillon, G.P.; Illes, J.C.; Isaacs, H.V.; Wilson, R.A. (2007) Patterns of gene expression in schistosomes: localization by whole mount in situ hybridization. Parasitology. 134(11):1589-97.
- Verjovski-Almeida, S.; DeMarco, R.; Martins, E.A.; Guimaraes, P.E.; Ojopi, E.P.; Paquola, A.C.; Piazza, J.P.; Nishiyama, M.Y.,Jr.; Kitajima, J.P.; Adamson, R.E.; Ashton, P.D.; Bonaldo, M.F.; Coulson, P.S.; Dillon, G.P.; et al. (2003) Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni. Nature Genetics. 35(2):148-157
Brief description of institution/company
AFFiRiS develops synthetic vaccines against chronic diseases with unmet medical needs. The antigens of these vaccines are short peptides which function as B-cell epitopes. The aim of an AFFITOPE vaccination is to induce antibody immune responses which will address each target structure with the relevant appropriate specificity. The T-cell help required is provided by a carrier protein such as KLH covalently linked to the peptides. The basis for these developments is the proprietary AFFITOME® technology.
Scientists
Dr. Günther Staffler
Function
Chief Technical Officer
Phone
Role in Consortium
Brief description of institution/company
CRISPR Therapeutics is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough genome-editing technology, into transformative medicines for serious human diseases. We are uniquely positioned to translate CRISPR-Cas9 technology into human therapeutics, thanks to our multi-disciplinary team of world-renowned academics, clinicians and drug developers.
CRISPR Therapeutics' vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK and Cambridge, Massachusetts.
Scientists
Dr. Rodger Novak
Department
CEO, Crispr Therapeutics Ltd.
Phone
Role in Consortium
Training
Brief CV
| 2013 - Present | Founder and CEO CRISPR Therapeutics |
| 2011 - 2013 | Vice President, Head TSU Infectious Diseases, Sanofi Global R&D |
| 2006 - 2011 | Chief Operating Officer and Founder of Nabriva Therapeutics AG |
| 2003 - 2006 | Deputy Head - Antibiotic Research Institute (ABRI), Sandoz Austria |
| 2001 | University Professor (Microbiology & Genetics), Vienna Biocenter, University of Vienna, Austria |
Selected Awards
| 2000 | The Merck ICAAC Young Investigator Award of the American Society for Microbiology – price of USD 10.000 |
| 1998 | ICAAC Program Committee Award of the American Society for Microbiology in the area of "Resistance: Mechanism and Consequences" – price of USD 5.000 |
| 1996 | Award for outstanding presentation in the section: Inflammatory Brain Diseases. International Congress of Neurology, Göttingen, Germany |
Prof. Dr. Emmanuelle Charpentier
Department
Regulation in Infection Biology / MPI for Infection Biology
Phone
+49 30 28460-410
office-charpentier@mpiib-berlin.mpg.de
Role in Consortium
Training
Photo © Humboldt-Foundation/Sven Müller
Brief CV
| Since 2015 | Director at the Max Planck Institute for Infection Biology, Berlin, Germany |
| 2013 - 2015 | Full Prof., AvH Prof.; MHH. Dept. (REGI) Head, HZI, Braunschweig, Germany |
| 2014 | Guest Prof., Lab Head; MIMS, UCMR, Dept. Mol. Biol., Umeå Univ., Umeå, Sweden |
| 2013 | Docent (Medical Microbiology); Faculty of Medicine, Umeå Univ., Umeå, Sweden |
| 2009 - 2013 | Assoc. Prof., Lab Head; The Laboratory for Mol. Infection Medicine Sweden, EMBL Nordic Node (MIMS), UCMR, Dept. Mol. Biol., Umeå Univ., Umeå, Sweden |
| 2006 - 2009 | Assoc. Prof., Lab Head; Max F. Perutz Laboratories, Univ. of Vienna, Vienna, Austria |
| 2006 | Priv.-Doz., Professorial Dissertation (Microbiology); Univ. of Vienna, Vienna, Austria |
| 2004 - 2006 | Assist. Prof., Lab Head; Dept. Microbiol. & Immuno., Univ. of Vienna, Vienna, Austria |
| 2002 - 2004 | Guest Prof., Lab Head; Inst. Microbiol. & Genet., Univ. of Vienna, Vienna, Austria |
| 1999 - 2002 | Research Assoc.; Skirball Inst. of Biomol. Medicine, New York, USA |
| 1999 | Research Assoc.; St. Jude Children's Research Hospital, Memphis, TN, USA |
| 1997 - 1999 | Research Assist.; New York Univ. Medical Center, New York, NY, USA |
| 1996 - 1997 | Post-doctoral Assoc.; The Rockefeller Univ., New York, NY, USA |
| 1995 - 1996 | Post-doctoral Assist.; Pasteur Inst., Paris, France |
| 1995 | Ph.D. Degree (Microbiology); Univ. P. & M. Curie, Pasteur Inst., Paris, France |
| 1992 | Master Degree (Microbiology); Univ. P. & M. Curie, Pasteur Inst., Paris, France |
Selected Awards
| 2015 | Umeå University EC Jubilee Award |
| 2015 | Gruber Prize in Genetics |
| 2015 | Hansen Family Award |
| 2015 | Princess of Asturias Award for Technical and Scientific Research |
| 2015 | Elected Fellow of the American Academy of Microbiology |
| 2015 | Louis Jeantet Prize for Medicine |
| 2015 | Ernst Jung Prize for Medicine |
| 2015 | Breakthrough Prize in Life Science |
| 2014 | Grand Prix Jean-Pierre Lecocq |
| 2014 | Dr Paul Janssen Award for Biomedical Research |
| 2014 | Elected EMBO Member |
| 2014 | Göran Gustafsson Prize |
| 2013 | Alexander von Humboldt (AvH) Professorship |
Keywords Research Activities
- Regulator mechanisms in processes of infection and immunity with a focus on Gram-positive bacterial pathogens, especially, we are interested in
- CRISPR-Cas: RNA-mediated interference in immunity
- Regulatory small RNAs
- Regulatory protein quality control
- Regulation by RNAs and proteins in innate immuntiy
Key publications or research/innovation products
- Doudna JA and Charpentier E. 2014. The new frontier of genome engineering with CRISPR-Cas9. Science 346(6213):1258096.
- Jinek M, Jiang F, Taylor DW, Stenberg SH, Kaya E, Ma E, Anders C, Hauer M, Zhou K, Lin S, Kaplan M, Iavarone AT, Charpentier E, Nogales E and Doudna JA. 2014. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science 343(6176):1247997.
- Fonfara I, Le Rhun A, Chylinski K, Makarova KS, Lécrivain AL, Bzdrenga J, Koonin EV and Charpentier E. 2014. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. Nucleic Acids Res. 42(4):2577-2590.
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA and Charpentier E. 2012. A programmable dual-RNA guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816-821.
- Deltcheva E, Chylinski K, Sharma C, Gonzales K, Chao Y, Pirzada ZA, Eckert M, Vogel J and Charpentier E. 2011. CRISPR RNA maturation by trans-encoded small RNA and host factor RNAse III. Nature 471(7340):602-607.
Brief description of institution/company
Eagle provides world-class bioinformatics services to commercial organisations supporting the management, analysis and exploitation of genomics and Next Generation Sequencing (NGS) related data. Eagle has worked with over 30 international blue-chip customers across the pharmaceutical, biotech, healthcare, crop science, biofuels, animal health, food and personal hygiene sectors. Eagle successfully addresses scientific information management challenges to life science R&D with a combination of cloud-based computing capabilities and bioinformatics expertise. -- from whole genome browsing configuration (eaglensembl), to genomic analysis workflow management (eaglehive), and an innovative platform for the cataloguing of large-scale datasets and metadata across an entire organisation (eaglecore). Eagle Genomic delivers on expert capabilities for accelerating R&D discovery.
Scientists
Eleanor Stanley
Department
Research and Development
Phone
+44 1223 654481
eleanor.stanley@eagelgenomics.com
Role in Consortium
Training and Secondments
 |
EMBL - EBI |
Website
Short Name
EMBL-EBI
Brief description of institution/company
EMBL-EBI research: About 20% of EMBL-EBI is devoted to collaborative, investigator-led research using computational approaches to unravel the secrets of life. Our research is carried out both in groups devoted solely to research and in some of the larger service teams that have associated research activities. All researchers have computational approaches as their major focus, but most also collaborate closely with experimentalists and even generate experimental data themselves.
Scientists
Dr. Cath Brooksbank
Department
Head of Training
Phone
+44 1223 492525
Website of Lab
Role in Consortium
Training
Brief CV
| 2012 - present: | Head of Training, EMBL-EBI |
| 2006 - 2012: | Head of Outreach and Training, EMBL-EBI |
| 2002 - 2006: | Scientific Outreach Officer, EMBL-EBI |
| 1993 - 2002: | Locum Subeditor, Associate Editor, Managing Editor and Editor of various journals (Nature Reviews Molecular Cell Biology, Nature Reviews Cancer, Elsevier Trends Journals, Molecular Medicine Today) |
| 1989 - 1993: | PhD at University of Cambridge (UK) |
| 1986 - 1989: | Medicine Training at University of Oxford (UK) |
Key publications or research/innovation products
- Welch, L. et al. (2014) Bioinformatics curriculum guidelines: toward a definition of core competencies. PloS Comput Biol. 10, e1003496
- Brooksbank, C. et al. (2014) The European Bioinformatics Institute's data resources 2014. Nucleic Acids Res. 42, 18–25
- Hardman, M. et al. (2013) LifeTrain: towards a European framework for continuing professional development in biomedical sciences Nature Rev. Drug Discov. 12, 407–408
- Klech, H. et al. (2012) European initiative towards quality standards in education and training for discovery, development and use of medicines. Eur. J. Pharmaceut. Sci. 45, 515–520
- Wright, V. A. et al. (2010) Bioinformatics training: Selecting an appropriate learning content management system – an example from the European Bioinformatics Institute. Brief. Bioinformat. 11, 552–562
Brief description of institution/company
Genomatix is one of the world's leading suppliers of technologies to analyze and interpret genomic data. With a focus on microarray and NGS data analysis, our hardware and software solutions also help to answer the typical questions posed by systems biology. Our approach: combine multiple lines of evidence to perform an integrated meta-analysis.
Scientists
Dr. Christian Zinser
Department
Consulting
Phone
+49 89 599766 0
Role in Consortium
Training and Secondments
Brief CV
| since 2010 | Head of Consulting, Genomatix Software GmbH, Munich, Germany |
| 2008 - 2010 | Head of Training, Genomatix Software GmbH, Munich, Germany |
| 2006 - 2007 | Application Scientist, Genomatix Software GmbH, Munich, Germany |
| 2005 - 2006 | Application Developer, Pixel GmbH, Gr‰felfing, Germany |
| 2001 - 2005 | Database Administrator, Ingenium Pharmaceuticals AG, Martinsried, Germany |
| 2000 - 2001 | Database Administrator, Staticon International GmbH, Martinsried, Germany |
| 1999 - 2000 | Training as Software Developer / Database Administrator, ptm Academy, Munich, Germany |
| 1996 - 1998 | Post-Doc at Botanical Institute, Ludwig Maximilian University of Munich, Germany |
| 1992 - 1996 | PhD thesis, Helmholtz Center Munich, Germany (formerly GSF National Research Center for Environment and Health) |
| 1987 - 1991 | Undergraduate studies in Biology, Ludwig Maximilian University of Munich, Germany |
| 1985 - 1987 | Undergraduate studies in Biology, University of Regensburg, Germany |
Selected Awards
| 2012 | "Industriepreis 2012" in the biotech category at Hannover Messe |
| 2012 | Finalists of Boston Children's Hospital's CLARITY challenge |
| 2011 | Illumina's Data Excellence (iDEA) Challenge 2011 "Most creative visualization" in the commercial category |
Key publications or research/innovation products
- Supper J, Gugenmus C, Wollnik J, Drueke T, Scherf M, Hahn A, Grote K, Bretschneider N, Klocke B, Zinser C, Cartharius K, Seifert M (2013) Detecting and visualizing gene fusions. Methods. 2013 Jan;59(1):S24-8
- Riedmaier I, Benes V, Blake J, Bretschneider N, Zinser C, Becker C, Meyer HH, Pfaffl MW (2012) RNA-Sequencing as Useful Screening Tool in the Combat against the Misuse of Anabolic Agents. Anal Chem. 2012 Aug 7;84(15):6863-8. Epub 2012 Jul 13
- Seitz V, Butzhammer P, Hirsch B, Hecht J, Gütgemann I, Ehlers A, Lenze D, Oker E, Sommerfeld A, von der Wall E, König C, Zinser C, Spang R, Hummel M (2011) Deep Sequencing of MYC DNA-Binding Sites in Burkitt Lymphoma. PLoS One. 2011;6(11):e26837. Epub 2011 Nov 10
- Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, Ravo M, Tarallo R, Luo S, Schroth GP, Seifert M, Zinser C, Chiusano ML, Traini A, De Bortoli M, Weisz A (2010) Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol. 2010 May;176, 2113-30
Brief description of institution/company
Novimmune SA (NI) is a privately held drug discovery and development company located in Geneva, Switzerland focusing on developing therapeutic antibodies for inflammatory diseases, autoimmune disorders and cancer. Novimmune's has created and advanced several products into clinical trials in patients. The staff of 100 people is divided across the departments of Research, Translational Sciences, Bioprocessing and Clinical Science/Safety/Operations.
Scientists
Marie H. Kosco-Vilbois, PhD
Department
Novimmune SA
Phone
+41 22 839 7141
Role in Consortium
Training
Brief CV
| Since 2005 | Chief Scientific Officer, NovImmune S.A., Geneva Switzerland |
| 2002 - 2005 | Director of Research, NovImmune S.A., Geneva Switzerland |
| 1998 - 2002 | Head of Immunology, Serono Research Institute, Geneva Switzerland |
| 1994 - 1998 | Head of Immunology Glaxo Wellcome Research Institute, Geneva |
| 1989 - 1994 | Scientific Member, Basel Institute for Immunology, Basel, Switzerland. |
| 1985 - 1989 | Postdoctoral Fellow, Department of Microbiology & Immunology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA USA |
| 1980 - 1985 | Doctor of Philosophy (Ph.D.), Department of Anatomy, Division of Immunology, Medical College of Virginia, VCU, Richmond, VA USA |
Keywords Research Activities
- Germinal center reactions
- Autoimmune diseases
- TLR4 biology
- Chemokines
- Cancer immunology
Key publications or research/innovation products
- Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurendon A, Gueneau F, Ravn U, Depoisier JF, Moine V, Raimondi S, Malinge P, Di Grazia L, Rousseau F, Poitevin Y, Calloud S, Cayatte PA, Alcoz M, Pontini G, Fagète S, Broyer L, Corbier M, Schrag D, Didelot G, Bosson N, Costes N, Cons L, Buatois V, Johnson Z, Ferlin W, Masternak K, Kosco-Vilbois M. (2015) Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun. Feb 12;6:6113.
- Giovannoni L, Muller YD, Lacotte S, Parnaud G, Borot S, Meier RP, Lavallard V, Bédat B, Toso C, Daubeuf B, Elson G, Shang L, Morel P, Kosco-Vilbois M, Bosco D, Berney T. (2015) Enhancement of islet engraftment and achievement of long-term islet allograft survival by Toll-like receptor 4 blockade. Transplantation. 2015 Jan;99(1):29-35.
- Shang L, Daubeuf B, Triantafilou M, Olden R, Dépis F, Raby AC, Herren S, Dos Santos A, Malinge P, Dunn-Siegrist I, Benmkaddem S, Geinoz A, Magistrelli G, Rousseau F, Buatois V, Salgado-Pires S, Reith W, Monteiro R, Pugin J, Leger O, Ferlin W, Kosco-Vilbois M, Triantafilou K, Elson G.(2014) Selective antibody intervention of Toll like Receptor 4 activation through Fc gamma receptor tethering. J Biol Chem. 289:15309-18.
- Zhang Y, Meyer-Hermann M, George LA, Figge MT, Khan M, Goodall M, Young SP, Reynolds A, Falciani F, Waisman A, Notley CA, Ehrenstein MR, Kosco-Vilbois M, Toellner KM. (2013) Germinal center B cells govern their own fate via antibody feedback. J Exp Med., 210(3):457-64.
- Garin A, Meyer-Hermann M, Contie M, Figge MT, Buatois V, Gunzer M, Toellner KM, Elson G, Kosco-Vilbois MH. (2010) Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation. Immunity. 33:84-95.
